Gibson Dunn Advises Dianthus Therapeutics on $719 Million Upsized Offering of Common Stock and Pre-Funded Warrants

Dianthus Therapeutics, Inc. was represented by Gibson Dunn in a public offering of its common stock and pre-funded warrants to buy common stock. Dianthus received total gross proceeds from the offering of about $719 million.